CClinicalTrials.gg
RecruitingNCT05942430Updated Sep 6, 2023

Autologous Costal Osteochondral Transplantation for Talar Osteochondral Lesions

An interventional study of Autologous costal osteochondral transplantation and Autologous iliac osteoperiosteal transplantation in Articular Cartilage Defect, sponsored by The Third Affiliated Hospital of Southern Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-09-06.

Sponsored by The Third Affiliated Hospital of Southern Medical University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the effectiveness and safety of autologous costal osteochondral transplantation in the treatment of Hepple Stage V talar osteochondral lesions, compared with autologous osteoperiosteal transplantation. The main question it aims to answer is:

  • Whether autologous costal osteochondral transplantation can achieve better clinical outcomes and cartilage repair quality with lower donor site morbidity than autologous osteoperiosteal transplantation in the treatment of Hepple Stage V talar osteochondral lesions.

Participants will be randomly assigned to the intervention group (undergoing autologous costal osteochondral transplantation) or the control group (undergoing autologous osteoperiosteal transplantation). Both groups of participants will receive the same postoperative rehabilitation process and follow-up evaluation.

02

Conditions studied

  • Articular Cartilage Defect

Keywords

  • costa
  • autologous osteochondral transplantation
  • autologous osteoperiosteal transplantation
  • osteochondral lesion of the talus
03

In context

Lead sponsor

The Third Affiliated Hospital of Southern Medical University is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Symptomatic Hepple stage V talar osteochondral lesions with a lesion depth ≥5 mm and an AOFAS score ≤80 points;
  • Failed conservative treatment for at least 6 months;
  • Unilateral talar osteochondral lesions without corresponding lesions on the tibial side;
  • Willingness to participate in this clinical trial and signing an informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Combined with lower limb deformity.
  • Combined with hip or knee joint diseases.
  • Combined with ipsilateral ankle arthritis with joint space narrowing .
  • Diagnosis of gouty arthritis of the ankle joint.
  • Combined with osteoporosis (T score \<-2.5).
  • Other conditions considered inappropriate for participation in this clinical trial by the researchers.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    The costa group

    Autologous costal osteochondral transplantation

    Procedure: Autologous costal osteochondral transplantation

  • Active comparator
    The ilium group

    Autologous iliac osteoperiosteal transplantation

    Procedure: Autologous iliac osteoperiosteal transplantation

Interventions

  • ProcedureAutologous costal osteochondral transplantation

    Operating steps: 1. Arthroscopic examination of the size and location of the talar osteochondral lesion; 2. Make a transverse incision (approximately 4 cm long) at the osteochondral junction of the fifth or sixth rib, and harvest an osteochondral column from the rib; 3. Thoroughly remove the talar osteochonral lesion through arthrotomy or Chevron osteotomy of the medial malleolus; 4. Trim the autograft according to the size of the lesion; 5. Fill the peri-lesion cavity with cancellous bone, and finally embed the costal osteochondral autograft into the talar defect, ensuring that the cartilage surface of the transplant to be flush with the normal talar cartilage around it; 6. Suture the joint capsule or reduct and fix the medial malleolus, and close the incision layer by layer.

  • ProcedureAutologous iliac osteoperiosteal transplantation

    Operating steps: 1. Arthroscopic examination of the size and location of the talar osteochondral lesion; 2. Make an incision along the anterior iliac crest. At the time of exposure, pay attention not to damage the periosteum. Obtain a cylindrical osteoperiosteal column by an appropriate-sized harvester tube. 3. Thoroughly remove the talar osteochonral lesion through arthrotomy or Chevron osteotomy of the medial malleolus; 4. Fill the peri-lesion cavity with cancellous bone, and finally embed the iliac osteoperiosteal autograft into the talar defect, ensuring that the periosteum surface of the transplant to be flush with the normal talar cartilage around it; 5. Suture the joint capsule or reduct and fix the medial malleolus, and close the incision layer by layer.

06

What researchers measure

Primary outcomes

  1. American Orthopedic Foot and Ankle Society (AOFAS) ankle-hindfoot scale score

    0-100

    Time frame: 24 months after surgery

Secondary outcomes

  1. American Orthopedic Foot and Ankle Society (AOFAS) ankle-hindfoot scale score

    0-100

    Time frame: 3, 6, 12 months after surgery

  2. International Cartilage Repair Society (ICRS) score

    0-12; based on arthroscopic examination

    Time frame: 12 months after surgery

  3. Numeric Rating Scale (NRS) for ankle pain during walking

    0-10

    Time frame: 3, 6, 12 and 24 months after surgery

  4. Foot and Ankle Ability Measure (FAAM) ADL subscale

    0-100

    Time frame: 12 and 24 months after surgery

  5. Foot and Ankle Ability Measure (FAAM) Sports subscale

    0-100

    Time frame: 12 and 24 months after surgery

  6. Tegner score

    0-10

    Time frame: 12 and 24 months after surgery

  7. Patients' satisfaction degree

    0-10

    Time frame: 24 months after surgery

  8. Bone union

    Based on computed tomography scan

    Time frame: 3 months after surgery or later

  9. Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score

    0-100; based on magnetic resonance imaging

    Time frame: 12 and 24 months after surgery

  10. Numeric Rating Scale (NRS) for donor-site pain

    0-10

    Time frame: 1, 2, 3, 6, 12 and 24 months after surgery

  11. Any other complications

    Any other complications

    Time frame: 1, 2, 3, 6, 12 and 24 months after surgery

07

Study locations

1 of 1 sites recruiting
  • The Third Affiliated Hospital of Southern Medical University
    Guangzhou, Guangdong 510630, China
    • Junyan Li · Contact · 00-86-20-62784067
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05942430
Lead sponsor
The Third Affiliated Hospital of Southern Medical University
Responsible party
Canjun Zeng (Director of the Department of Foot and Ankle Surgery, The Third Affiliated Hospital of Southern Medical University) — Principal investigator
First posted
Jul 12, 2023
Start date
Sep 1, 2023
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Sep 6, 2023

Study contacts

Hao Guo, MD
Contact
416363977@qq.com
+8617612003968
Canjun Zeng, PhD
principal investigator · The Third Affiliated Hospital of Southern Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion